Side-by-side comparison of AI visibility scores, market position, and capabilities
Indoor vertical farming company using AI-optimized growing systems. San Francisco, CA. Raised $940M+ including $400M from SoftBank. Partners with Walmart for US farms.
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has raised over $940 million from investors including SoftBank Vision Fund, which invested $200 million in 2017, and has positioned itself as the technology leader in data-driven indoor agriculture.\n\nPlenty's farms use precisely controlled light, temperature, humidity, and nutrient conditions to grow crops that are free from pesticides, use 99% less land, and consume significantly less water than conventional field agriculture. The company's AI systems continuously optimize growing conditions based on sensor data, learning to improve yields and quality across crops and growing cycles.\n\nIn 2022, Plenty announced a landmark partnership with Walmart to supply leafy greens from a new large-scale facility in Compton, California. This partnership provided both a major commercial anchor and significant additional funding from Walmart, validating Plenty's technology and business model at scale. The company also operates a dedicated strawberry R&D partnership with Driscoll's, the world's largest berry company, demonstrating the platform's potential beyond leafy greens.
Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.
AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.